Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

277

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

277 results for “Lapatinib”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov40/100

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

ClinicalTrials.gov study NCT00272987. IPD Sharing: YES. Countries: 2. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

ClinicalTrials.gov study NCT01160211. IPD Sharing: YES. Countries: 29. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic S

ClinicalTrials.gov study NCT01808573. IPD Sharing: YES. Countries: 28. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

ClinicalTrials.gov study NCT00709761. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

ClinicalTrials.gov study NCT00263588. IPD Sharing: UNDECIDED. Countries: 17. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

ClinicalTrials.gov study NCT00667251. IPD Sharing: YES. Countries: 21. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

ClinicalTrials.gov study NCT00820222. IPD Sharing: UNDECIDED. Countries: 14. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

ClinicalTrials.gov study NCT00553358. IPD Sharing: YES. Countries: 24. Publications: 10.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

ClinicalTrials.gov study NCT00490139. IPD Sharing: YES. Countries: 44. Publications: 7.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

ClinicalTrials.gov study NCT00680901. IPD Sharing: YES. Countries: 23. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

ClinicalTrials.gov study NCT00073528. IPD Sharing: YES. Countries: 29. Publications: 6.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Lapatinib and Bevacizumab for Metastatic Breast Cancer

ClinicalTrials.gov study NCT00444535. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

ClinicalTrials.gov study NCT00508274. IPD Sharing: YES. Countries: 2. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

ClinicalTrials.gov study NCT00777101. IPD Sharing: Not stated. Countries: 31. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

ClinicalTrials.gov study NCT00526669. IPD Sharing: Not stated. Countries: 6. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

ClinicalTrials.gov study NCT00356811. IPD Sharing: Not stated. Countries: 4. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

ClinicalTrials.gov study NCT00524303. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

ClinicalTrials.gov study NCT00390455. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

ClinicalTrials.gov study NCT00320385. IPD Sharing: Not stated. Countries: 13. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

ClinicalTrials.gov study NCT01769508. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record